Qube Research & Technologies LTD Geron Corp Transaction History

Qube Research & Technologies LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.1 - $5.09 $1.16 Million - $1.91 Million	375,395 New	375,395 $1.59 Million
Q4 2023 Feb 13, 2024	BUY	$1.74 - $2.31 $812,012 - $1.08 Million	466,674 New	466,674 $984,000
Q2 2023 Aug 14, 2023	SELL	$1.97 - $3.69 $172,985 - $324,018	-87,810 Reduced 69.9%	37,805 $121,000
Q1 2023 May 15, 2023	BUY	$2.14 - $3.4 $268,816 - $427,091	125,615 New	125,615 $272,000
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $481,850 - $848,287	288,533 New	288,533 $675,000
Q1 2021 May 14, 2021	SELL	$1.52 - $2.1 $91,385 - $126,256	-60,122 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$1.55 - $2.05 $93,189 - $123,250	60,122 New	60,122 $96,000

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.51B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.